Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial
Simeon Schietzel(University of Bern), Daniel G. Fuster(University of Bern), Bruno Vogt(Hypertension Institute), Sven Trelle(Institute of Social and Preventive Medicine), Matthias B. Moor(University of Bern), Felix Rintelen(University of Bern), Nicolas Faller(University Hospital of Bern), Grazia M. Cereghetti(University Hospital of Bern), Lia Bally(Diabetes Australia)
Cited by 31
Related Papers
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
GetReal in network meta‐analysis: a review of the methodology
|Research Synthesis Methods|2016|415
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
|Endocrine Reviews|2022|398
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|366